Consuelo Pedrós

Consuelo Pedrós

Auto-generated profile, based on publicly available information

Consuelo Pedrós

Hospital General Universitario de Valencia

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2005 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
AFAntonio Vallano Ferraz
Antonio Vallano Ferraz
GCG. Cereza
G. Cereza
CPC. Pedròs
C. Pedròs
AAA. Agustí
A. Agustí
IDI. Danés
I. Danés
JAJ. M. Arnau
J. M. Arnau
Aim: To describe the opinions of hospital physicians concerning problems regarding the spontaneous reporting of adverse drug reactions (ADRs) and ways to solve them.Methods: A qualitative study was carried out. Fifteen focus groups were conducted among physicians working in a tertiary teaching hospital. A total of 208 physicians from different medical specialities participated. The focus group discussions were recorded by three different observers and the transcripts of each session were analysed for issues and themes emerging from the text.Results: Four types of obstacles to spontaneous reporting were considered particularly important: (i) problems with the ADRS diagnosis; (ii) problems with the usual workload and lack of time; (iii) problems related to the organization and activities of the pharmacovigilance system; (iv) and problems related to potential conflicts. The potential solutions suggested for improving spontaneous reporting were to define the kind of ADRS which should be reported, to facilitate an easy contact and quick access to the hospital pharmacovigilance system, to facilitate information and support for reporting and feedback of pharmacovigilance activities.Conclusions: The perception of the different obstacles by the hospital physicians is an important factor in determining the causes of the underreporting of ADRs and addressing these obstacles could lead to an improvement in spontaneous reporting. A closer relationship between the doctors and the pharmacovigilance centre is suggested as a means of solving these problems. More information is needed to improve the spontaneous reporting of ADRS in specialized healthcare.

21 December 2013 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
CPConsuelo Pedrós
Consuelo Pedrós
BQBeatriz Quintana
Beatriz Quintana
MRMireia Rebolledo
Mireia Rebolledo
NPNúria Porta
Núria Porta
AFAntonio Vallano Ferraz
Antonio Vallano Ferraz
JAJosep Maria Arnau
Josep Maria Arnau

7 November 2015 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
CPConsuelo Pedrós
Consuelo Pedrós
FFFrancesc Formiga
Francesc Formiga
XCXavier Corbella
Xavier Corbella
JAJosep Maria Arnau
Josep Maria Arnau

1 January 2009 in Drug Safety
Verified
Journal Article
Closed access
PDF file
CPConsuelo Pedrós
Consuelo Pedrós
AFAntonio Vallano Ferraz
Antonio Vallano Ferraz
GCGloria Cereza
Gloria Cereza
GMGemma Mendoza-Aran
Gemma Mendoza-Aran
AAAntònia Agustí
Antònia Agustí
JAJosep M. Arnau
Josep M. Arnau

1 January 2003 in Drug Safety
Verified
Journal Article
Closed access
PDF file
JCJosep Maria Castel
Josep Maria Castel
Albert FiguerasAlbert Figueras
Albert Figueras
CPConsuelo Pedrós
Consuelo Pedrós
JLJoan-Ramon Laporte
Joan-Ramon Laporte
DCDolors Capellà
Dolors Capellà

1 July 2012 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
SGSilvia Gómez-Zorrilla
Silvia Gómez-Zorrilla
AFAntonio Vallano Ferraz
Antonio Vallano Ferraz
CPConsuelo Pedrós
Consuelo Pedrós
MLMiguel Lemus
Miguel Lemus
CPCarmen Peña
Carmen Peña
OBJECTIVE: To describe a case of levetiracetam-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. CASE SUMMARY: A 31-year-old white male with a low-grade astrocytoma presenting with tonic-clonic seizures was treated with levetiracetam 1 g twice daily and dexamethasone (initial dosage 12 mg/day, tapered down to 2 mg/day). On day 45 after levetiracetam initiation, dexamethasone was discontinued and levetiracetam continued. The patient developed fever and dyspnea on day 46 and was admitted to the hospital on day 49. A chest X-ray showed bilateral pulmonary interstitial infiltrates, and laboratory tests showed elevated lactate dehydrogenase (LDH; 288 U/L [reference range <204]), ferritin (223 ng/mL [13–178]), and C-reactive protein (CRP; 3.1 mg/dL [<0.5]). Neurologic fever was suspected and the reinitiation of dexamethasone at 6 mg/day was followed by improvement of all symptoms; the patient was discharged on day 55 with dexamethasone 4 mg/day for 2 more days. On day 59, 2 days after the withdrawal of dexamethasone for the second time, the patient presented with a pruritic erythematous maculopapular rash along with recurrence of fever and dyspnea, and was admitted to the hospital. A chest X-ray showed reappearance of the bilateral pulmonary interstitial infiltrates, and laboratory tests showed impaired liver function (alanine aminotransferase 60 U/L [reference range <56], aspartate aminotransferase 53 U/L [<30], LDH 516 U/L, ferritin 419 ng/mL, and CRP 2.6). A diagnosis of DRESS syndrome was suspected and levetiracetam was discontinued. Upon levetiracetam withdrawal, the patient's symptoms resolved by day 66, and radiological images showed resolution of the interstitial infiltrate by day 68. The patient was discharged on day 68. Low-grade fever persisted until day 71, with no other symptoms. During a 2-month follow-up period, liver function test results returned to normal. DISCUSSION: DRESS is a hypersensitivity reaction to several drugs, mainly antiepileptic drugs (AEDs), characterized by cutaneous, hematologic, and visceral involvement. Levetiracetam is structurally and pharmacologically unrelated to other AEDs. Previously, only one case of levetiracetam-induced DRESS syndrome had been reported, which required corticosteroids to control symptoms. We describe a case of levetiracetam-induced DRESS syndrome presenting with pneumonitis and hepatitis that resolved with levetiracetam withdrawal. Our patient was classified as a definitive DRESS case according to the RegiSCAR scoring system, which grades DRESS cases. According to the Naranjo probability scale, the adverse drug reaction was considered probable. CONCLUSIONS: Although levetiracetam is usually well tolerated, clinicians should be aware of the potential for it to cause DRESS syndrome.